NASDAQ · Biotechnology

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock

$5.38 +2.09% NASDAQ: CRBP Healthcare

Valuation

MetricValue
Price$5.38
Market Cap$99.68M
P/E Ratio-0.95
P/B Ratio1.16
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$20.56
52-Week Low$5.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-87.05%
ROA-80.25%
ROCE-101.30%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio7.95

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$0
Operating Profit$-56.0M$-35.0M$-45.0M$-49.0M$-85.0M
Net Profit$-46.0M$-56.0M$-45.0M$-40.0M$-79.0M
EPS$-11.13$-10.15$-10.31$-3.68$-5.90
Op Margin-6350.1%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$108.0M$66.0M$28.0M$156.0M$168.0M
Total Liabilities$39.0M$33.0M$35.0M$13.0M$21.0M
Cash$25.0M$17.0M$14.0M$17.0M$28.0M
Borrowings$27.0M$25.0M$21.0M$3.0M$2.0M

Latest News

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer GlobeNewswire · Jul 6, 2026 Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating MT Newswires · Jun 17, 2026 Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near MarketBeat · Jun 9, 2026 Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study MarketBeat · Jun 1, 2026 Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-48.0M$-38.0M$-36.1B$-42.0M$-64.0M
Investing Cash Flow$-73.0M$30.0M$35.6B$-121.0M$-2.0M
Financing Cash Flow$-2.0M$0$-191.0M$0$0
Net Cash Flow$-61.0M$-8.0M$-3.3B$3.0M$11.0M
Free Cash Flow$-48.0M$-38.0M$-36.1B$-42.0M$-64.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA-0.93
FCF Yield-76.33%
Quick Ratio5.71
Interest Coverage0.00
Return 1Y11.17%
Return 3Y16.82%
Return 5Y-79.82%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is led by CEO Yuval Cohen, employs 28 people, headquartered in US, publicly traded since 2014.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock trades at $5.38 with a market capitalization of $99.68M. The stock is valued at a price-to-earnings (P/E) ratio of -0.95, price-to-book of 1.16, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.22 and $20.56, and currently trades 73.8% below its 52-week high.

On profitability, Corbus Pharmaceuticals Holdings, Inc. generates a return on equity (ROE) of -87.05%, return on capital employed of -101.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides